Aptevo Therapeutics (APVO) Competitors $3.66 -0.73 (-16.63%) Closing price 04:00 PM EasternExtended Trading$3.53 -0.13 (-3.55%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO vs. CHRO, APLM, SBFM, PMCB, MYNZ, OMGA, KTTA, AIM, AEZS, and CELZShould you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Chromocell Therapeutics (CHRO), Apollomics (APLM), Sunshine Biopharma (SBFM), PharmaCyte Biotech (PMCB), Mainz Biomed (MYNZ), Omega Therapeutics (OMGA), Pasithea Therapeutics (KTTA), AIM ImmunoTech (AIM), Aeterna Zentaris (AEZS), and Creative Medical Technology (CELZ). These companies are all part of the "pharmaceutical products" industry. Aptevo Therapeutics vs. Its Competitors Chromocell Therapeutics Apollomics Sunshine Biopharma PharmaCyte Biotech Mainz Biomed Omega Therapeutics Pasithea Therapeutics AIM ImmunoTech Aeterna Zentaris Creative Medical Technology Chromocell Therapeutics (NYSE:CHRO) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment. Which has stronger earnings and valuation, CHRO or APVO? Chromocell Therapeutics has higher earnings, but lower revenue than Aptevo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38M-$1.24-0.98Aptevo Therapeutics$3.11M0.48-$24.13MN/AN/A Does the MarketBeat Community prefer CHRO or APVO? Aptevo Therapeutics received 198 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Chromocell Therapeutics an outperform vote while only 49.75% of users gave Aptevo Therapeutics an outperform vote. CompanyUnderperformOutperformChromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesAptevo TherapeuticsOutperform Votes19949.75% Underperform Votes20150.25% Do institutionals & insiders have more ownership in CHRO or APVO? 78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by company insiders. Comparatively, 0.0% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is CHRO or APVO more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% Aptevo Therapeutics N/A -488.93%-152.51% Does the media favor CHRO or APVO? In the previous week, Aptevo Therapeutics had 3 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 4 mentions for Aptevo Therapeutics and 1 mentions for Chromocell Therapeutics. Chromocell Therapeutics' average media sentiment score of 1.00 beat Aptevo Therapeutics' score of 0.77 indicating that Chromocell Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Chromocell Therapeutics Positive Aptevo Therapeutics Positive Do analysts recommend CHRO or APVO? Aptevo Therapeutics has a consensus target price of $219,040.00, suggesting a potential upside of 5,984,599.45%. Given Aptevo Therapeutics' higher possible upside, analysts clearly believe Aptevo Therapeutics is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aptevo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CHRO or APVO? Chromocell Therapeutics has a beta of 3.22, indicating that its stock price is 222% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.75, indicating that its stock price is 475% more volatile than the S&P 500. SummaryChromocell Therapeutics and Aptevo Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APVO vs. The Competition Export to ExcelMetricAptevo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.48M$6.78B$5.51B$8.62BDividend YieldN/A2.48%5.27%4.17%P/E RatioN/A8.3626.6019.77Price / Sales0.48262.40404.54150.26Price / CashN/A65.8538.2534.64Price / Book1.126.567.074.68Net Income-$24.13M$142.76M$3.21B$247.80M7 Day Performance-21.79%-0.36%0.63%0.12%1 Month Performance-42.81%8.78%7.59%4.02%1 Year Performance-99.98%4.36%33.47%15.45% Aptevo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APVOAptevo Therapeutics2.8114 of 5 stars$3.66-16.6%$219,040.00+5,984,599.5%-100.0%$1.48M$3.11M0.0050News CoverageShort Interest ↓Gap DownCHROChromocell Therapeutics1.1726 of 5 stars$1.21+6.2%N/A-5.7%$7.52MN/A-0.984Short Interest ↓Gap UpAPLMApollomics1.2398 of 5 stars$6.75+3.8%N/A-68.0%$7.45M$1.22M0.0045Negative NewsGap DownSBFMSunshine Biopharma2.8752 of 5 stars$1.57+4.0%$15.00+855.4%+369.7%$7.15M$36.23M-0.013PMCBPharmaCyte Biotech1.2331 of 5 stars$1.04+2.0%N/A-53.9%$7.14MN/A1.964MYNZMainz Biomed2.6271 of 5 stars$2.06-1.0%$14.00+579.6%-92.7%$7.09M$893.99K-0.0330Gap DownOMGAOmega Therapeutics1.9791 of 5 stars$0.13-21.8%$9.20+7,260.0%-93.8%$6.92M$8.10M-0.09120Upcoming EarningsGap UpKTTAPasithea Therapeutics1.5677 of 5 stars$0.90+1.6%N/A-85.1%$6.70MN/A-0.083Short Interest ↓AIMAIM ImmunoTech2.0449 of 5 stars$0.09-22.3%$2.75+2,908.8%-79.6%$6.61M$170K-0.1920News CoverageGap DownHigh Trading VolumeAEZSAeterna ZentarisN/A$3.61-3.0%N/A-44.6%$6.47M$2.37M-0.2420CELZCreative Medical Technology0.4351 of 5 stars$2.45+2.5%N/A-47.9%$6.34M$14K-0.645Short Interest ↑Gap Down Related Companies and Tools Related Companies CHRO Alternatives APLM Alternatives SBFM Alternatives PMCB Alternatives MYNZ Alternatives OMGA Alternatives KTTA Alternatives AIM Alternatives AEZS Alternatives CELZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APVO) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSomething Big Is Coming...Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
